[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100485857":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":16,"centralContacts":21,"locations":30,"responsibleParty":46,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University Hospital, Geneva","OTHER",[8,12,14],{"label":9,"type":10,"description":11,"interventionNames":10},"Cachectic patients with pancreatic cancer",null,"Measurements and sample collection at one timepoint.",{"label":13,"type":10,"description":11,"interventionNames":10},"Non-cachectic patients with pancreatic cancer",{"label":15,"type":10,"description":11,"interventionNames":10},"Healthy volunteers",[17],{"name":18,"affiliation":19,"role":20},"Laurence Genton Graf, Prof","Geneva University Hospitals (HUG)","PRINCIPAL_INVESTIGATOR",[22,26],{"name":18,"role":23,"phone":24,"phoneExt":10,"email":25},"CONTACT","+41 22 3729344","laurence.genton@hcuge.ch",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Alexandra Hemmer, MSc","+41795530491","alexandra.hemmer@hcuge.ch",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Geneva University Hospitals","RECRUITING","Geneva","1211","Switzerland","CH",{"type":39,"coordinates":40},"Point",[41,42],6.14569,46.20222,{"lat":42,"lon":41},[45],{"name":18,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Genton Graf Laurence","Principal Investigator","100485857","microbiota-and-pancreatic-cancer-cachexia-100485857",false,"NCT05606523","Microbiota and Pancreatic Cancer Cachexia","Can Fecal Microbiota Transplantation of Cachectic Patients with Pancreas Cancer Impair Body Weight Gain in Germ-free Mice? the EXTRA Study","EXTRA","Inclusion Criteria:\n\nPatients with pancreatic cancer (n=12)\n\n* ≥18 years and\n* Newly diagnosed of pancreatic adenocarcinoma (local or metastatic) and\n* Tube feeding or parenteral nutrition ≤ 14 days\n\nCachectic pancreatic cancer patients (n=6)\n\n* Cachexia according to the Fearon criteria 1: involuntary weight loss \\>5% over the last 6 months, or any level of weight loss \\>2% and a BMI \\\u003C20 kg\u002Fm2 or sarcopenia. Sarcopenia will be diagnosed by BIA (fat-free mass index is \\\u003C17 kg\u002Fm2 in men and \\\u003C15 kg\u002Fm2 in women) 81, and not by CT, as it is faster and can be performed at the bedside of the patient. Non-cachectic pancreatic cancer patients (n=6)\n* Normal nutritional state: weight stability (± 2% of habitual weight) over the last 6 months, no anorexia before the diagnosis (appetite rating on a visual analogue scale of 100mm), no known impaired glucose tolerance.\n\nHealthy matched subjects (n=12)\n\n* ≥18 years and\n* BMI between 18.5 and 30 kg\u002Fm2 and\n* Absence of chronic or acute disease and\n* Matching for gender and age (± 5 years) with an included pancreatic cancer patient\n\nExclusion Criteria:\n\n* \\\u003C 18 years or\n* Inability to give consent or\n* Insufficient knowledge of project language (French, German) or\n* Pancreatic adenocarcinoma already treated by chemo- or radiotherapy, or major surgery as duodenopancreatectomy or biliary diversion\n* Known rheumatologic or immunologic diseases\n* Therapeutic antibiotics or immunosuppressive drugs (for instance glucocorticoids, cytostatics, antibodies) in the 30 days preceding the inclusion",true,"ALL","18 Years",{"count":62,"type":63},24,"ESTIMATED","OBSERVATIONAL","This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.",[67,68,69],"Pancreatic Cancer","Microbiota","Cachexia","2024-12-03",{"date":72,"type":73},"2024-12-06","ACTUAL",{"date":75,"type":73},"2022-08-01",{"date":77,"type":63},"2025-04-30",{"name":48,"class":6},1]